Cellceutix Reports Positive Interim Results from Brilacidin Phase 2 Clinical Trial

Cellceutix Reports Positive Interim Results from Brilacidin Phase 2 Clinical Trial
Positive interim results were reported in the first two groups of ulcerative colitis patients being treated with Brilacidin (PMX-30063) in a dose-escalating Phase 2 clinical trial. Patients for a third and final group — testing the highest dose — are now being recruited. The open-label and proof-of-concept study is testing the treatment’s safety and effectiveness at three dose levels

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *